{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:27:57Z","timestamp":1794540477329,"version":"4.9.1"},"reference-count":217,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Singapore Ministry of Education","doi-asserted-by":"publisher","award":["RG30\/20"],"award-info":[{"award-number":["RG30\/20"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>NAFLD is the most common chronic liver disease worldwide, occurring in both obese and lean patients. It can lead to life-threatening liver diseases and nonhepatic complications, such as cirrhosis and cardiovascular diseases, that burden public health and the health care system. Current care is weight loss through diet and exercise, which is a challenging goal to achieve. However, there are no FDA-approved pharmacotherapies for NAFLD. This review thoroughly examines the clinical trial findings from 22 drugs (Phase 2 and above) and evaluates the future direction that trials should take for further drug development. These trialed drugs can broadly be categorized into five groups\u2014hypoglycemic, lipid-lowering, bile-pathway, anti-inflammatory, and others, which include nutraceuticals. The multitude of challenges faced in these yet-to-be-approved NAFLD drug trials provided insight into a few areas of improvement worth considering. These include drug repurposing, combinations, noninvasive outcomes, standardization, adverse event alleviation, and the need for precision medicine with more extensive consideration of NAFLD heterogenicity in drug trials. Understandably, every evolution of the drug development landscape lies with its own set of challenges. However, this paper believes in the importance of always learning from lessons of the past, with each potential improvement pushing clinical trials an additional step forward toward discovering appropriate drugs for effective NAFLD management.<\/jats:p>","DOI":"10.3390\/ijms24010158","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T01:33:12Z","timestamp":1671672792000},"page":"158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-2680","authenticated-orcid":false,"given":"Joel Yeh Siang","family":"Chen","sequence":"first","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-1688","authenticated-orcid":false,"given":"Damien","family":"Chua","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa Odelia","family":"Lim","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, Nanyang Technological University Singapore, 60 Nanyang Drive, Singapore 637551, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Xi","family":"Ho","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-7341","authenticated-orcid":false,"given":"Nguan Soon","family":"Tan","sequence":"additional","affiliation":[{"name":"Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, Singapore"},{"name":"School of Biological Sciences, Nanyang Technological University Singapore, 60 Nanyang Drive, Singapore 637551, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","article-title":"National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants","volume":"377","author":"Finucane","year":"2011","journal-title":"Lancet"},{"key":"ref_4","unstructured":"(2022, September 08). Definition & Facts of NAFLD & NASH, Available online: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., and Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jdiacomp.2018.08.001","article-title":"Body fat, metabolic syndrome and hyperglycemia in South Asians","volume":"32","author":"Misra","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fendo.2020.00616","article-title":"Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy","volume":"11","author":"Ginsberg","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1172\/JCI93465","article-title":"Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis","volume":"127","author":"Caussy","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101049","DOI":"10.1016\/j.molmet.2020.101049","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis","volume":"50","author":"Mikhailidis","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"979515","DOI":"10.1155\/2015\/979515","article-title":"Gut Microbiota: Association with NAFLD and Metabolic Disturbances","volume":"2015","author":"Lau","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.31557\/APJCP.2018.19.11.3301","article-title":"Clinical Outcome and Predictive Factors of Variceal Bleeding in Patients with Hepatocellular Carcinoma in Thailand","volume":"19","author":"Kerdsuknirun","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"597583","DOI":"10.3389\/fendo.2020.597583","article-title":"Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides","volume":"11","author":"Korinkova","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1185\/03007995.2010.506375","article-title":"Population-based risk factors and resource utilization for HCC: US perspective","volume":"26","author":"Sanyal","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep4.1143","article-title":"Lean NAFLD: A not so benign condition?","volume":"2","author":"VanWagner","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20170959","DOI":"10.1259\/bjr.20170959","article-title":"Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging","volume":"91","author":"Zhang","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD","volume":"18","author":"Tamaki","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1148\/radiol.2020191152","article-title":"Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US","volume":"295","author":"Han","year":"2020","journal-title":"Radiology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/apt.13981","article-title":"Randomised clinical trial: The efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jhep.2019.09.018","article-title":"Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis","volume":"72","author":"Bril","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pasanta, D., Htun, K.T., Pan, J., Tungjai, M., Kaewjaeng, S., Kim, H., Kaewkhao, J., and Kothan, S. (2021). Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050842"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2017.03.006","article-title":"Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?","volume":"41","author":"Gargallo","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/diacare.23.1.57","article-title":"Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity","volume":"23","author":"Bonora","year":"2000","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00125-017-4340-1","article-title":"Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: A population-based and inter-laboratory study","volume":"60","author":"Isokuortti","year":"2017","journal-title":"Diabetologia"},{"key":"ref_30","first-page":"281","article-title":"Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India","volume":"28","author":"Pathik","year":"2015","journal-title":"Ann. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4292\/wjgpt.v7.i1.91","article-title":"Clinical applications, limitations and future role of transient elastography in the management of liver disease","volume":"7","author":"Chang","year":"2016","journal-title":"World J. Gastrointest Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10851","DOI":"10.3748\/wjg.v20.i31.10851","article-title":"Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future","volume":"20","author":"Fitzpatrick","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/ceh.2018.78120","article-title":"A systematic review of the present and future of non-alcoholic fatty liver disease","volume":"4","author":"Lucas","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"m4747","DOI":"10.1136\/bmj.m4747","article-title":"Management of non-alcoholic fatty liver disease","volume":"372","author":"Petroni","year":"2021","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1007\/s10620-020-06673-w","article-title":"Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease","volume":"66","author":"Stine","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","article-title":"Bariatric surgery in patients with non-alcoholic fatty liver disease\u2014From pathophysiology to clinical effects","volume":"11","author":"Laursen","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1007\/s11695-021-05390-1","article-title":"Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass","volume":"31","author":"Schmitz","year":"2021","journal-title":"Obes. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tgh.2019.10.12","article-title":"Nonalcoholic steatohepatitis recurrence after liver transplant","volume":"5","author":"Taneja","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s13643-019-1200-8","article-title":"Diabetes drugs for nonalcoholic fatty liver disease: A systematic review","volume":"8","author":"Blazina","year":"2019","journal-title":"Syst. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to Pioglitazone in Patients with Nonalcoholic Steatohepatitis with vs. without Type 2 Diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes: A Randomized Controlled Trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jare.2020.01.008","article-title":"An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes","volume":"23","author":"Bansal","year":"2020","journal-title":"J. Adv. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lange, N.F., Graf, V., Caussy, C., and Dufour, J.F. (2022). PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084305"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Prikhodko, V.A., Bezborodkina, N.N., and Okovityi, S.V. (2022). Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020274"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.21037\/tgh-20-247","article-title":"Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis","volume":"6","author":"Satiya","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_55","first-page":"60","article-title":"An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents","volume":"9","author":"Bojanic","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e13335","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"768850","DOI":"10.3389\/fendo.2021.768850","article-title":"Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence","volume":"12","author":"Yabiku","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand J. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1756283X09105462","article-title":"The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial","volume":"2","author":"Shields","year":"2009","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0b013e32835cc949","article-title":"Peroxisome proliferator-activated receptor delta: A multifaceted metabolic player","volume":"24","author":"Bojic","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e005855","DOI":"10.1161\/CIRCHEARTFAILURE.118.005855","article-title":"Understanding Contemporary Use of Thiazolidinediones","volume":"12","author":"Arnold","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1073\/pnas.1303360110","article-title":"Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier","volume":"110","author":"Divakaruni","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cmet.2015.07.028","article-title":"Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling","volume":"22","author":"McCommis","year":"2015","journal-title":"Cell Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100807","DOI":"10.1016\/j.jbc.2021.100807","article-title":"Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide","volume":"296","author":"Kamm","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_77","unstructured":"(2022, September 09). Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH. Available online: https:\/\/inventivapharma.com\/inventiva-receives-fda-breakthrough-therapy-designation-for-lead-drug-candidate-lanifibranor-in-nash\/."},{"key":"ref_78","unstructured":"Highleyman, L. (2022, September 08). Lanifibranor Both Resolves NASH and Reduces Liver Fibrosis. Available online: https:\/\/www.hepmag.com\/article\/lanifibranor-resolves-nash-reduces-liver-fibrosis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/13543784.2014.954034","article-title":"GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes","volume":"23","author":"Cariou","year":"2014","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int."},{"key":"ref_82","unstructured":"GENFIT (2020). GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis, GENFIT."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: Involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","article-title":"No direct effect of SGLT2 activity on glucagon secretion","volume":"62","author":"Kuhre","year":"2019","journal-title":"Diabetologia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects without Diabetes and Patients with Type 2 Diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/jc.2018-00969","article-title":"Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients with Type 2 Diabetes","volume":"104","author":"Lundkvist","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2337\/dbi19-0035","article-title":"A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets","volume":"69","author":"Hodson","year":"2020","journal-title":"Diabetes"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4093\/dmj.2020.0115","article-title":"Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming","volume":"44","author":"Jeong","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","article-title":"Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study","volume":"151","author":"Ku","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/dom.14054","article-title":"Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme","volume":"22","author":"Thethi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"541","DOI":"10.21037\/hbsn-21-231","article-title":"Semaglutide for nonalcoholic steatohepatitis: Closer to a solution?","volume":"10","author":"Liava","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_98","unstructured":"FDA (2019). FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"496453","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"Ohki","year":"2012","journal-title":"Sci. World J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcjd.2021.08.012","article-title":"Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL\/6J Mice","volume":"46","author":"Liu","year":"2022","journal-title":"Can. J. Diabetes"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e14622","DOI":"10.1111\/dme.14622","article-title":"First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs","volume":"38","author":"Campbell","year":"2021","journal-title":"Diabet. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1194\/jlr.M040451","article-title":"Contrasting metabolic effects of medium- versus long-chain fatty acids in skeletal muscle","volume":"54","author":"Montgomery","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10545-009-1126-8","article-title":"Treatment recommendations in long-chain fatty acid oxidation defects: Consensus from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.30674","article-title":"MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)","volume":"70","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00535-010-0203-y","article-title":"Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH","volume":"45","author":"Kimura","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1556\/oh.2009.28624","article-title":"Efficacy and safety of ezetimibe\/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"150","author":"Abel","year":"2009","journal-title":"Orv. Hetil."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5001\/omj.2014.93","article-title":"Statin associated hepatic adverse effects: A retrospective review from a regional hospital in sultanate of oman","volume":"29","author":"Jose","year":"2014","journal-title":"Oman Med. J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial","volume":"102","author":"Bril","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.3748\/wjg.v26.i34.5101","article-title":"Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation","volume":"26","author":"Bilbao","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_116","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jcmgh.2021.01.012","article-title":"Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH","volume":"11","author":"Cariello","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e00329","DOI":"10.1002\/prp2.329","article-title":"Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes","volume":"5","author":"Zhang","year":"2017","journal-title":"Pharm. Res. Perspect."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_120","unstructured":"Intercept (2022). Intercept Announces Positive Data in Fibrosis due to Nash from a New Analysis of Its Phase 3 Regenerate Study of Obeticholic Acid (OCA), Intercept Pharmaceuticals, Inc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fphys.2019.00770","article-title":"The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)","volume":"10","author":"Drescher","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/acsmedchemlett.9b00611","article-title":"Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors","volume":"11","author":"Xin","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): An investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e000365","DOI":"10.1136\/openhrt-2015-000365","article-title":"Pentoxifylline for vascular health: A brief review of the literature","volume":"3","author":"McCarty","year":"2016","journal-title":"Open Heart"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1665-2681(19)31539-X","article-title":"Pentoxifylline for the treatment of non-alcoholic steatohepatitis: A randomized controlled trial","volume":"10","author":"Koppe","year":"2011","journal-title":"Ann. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","article-title":"Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis","volume":"20","author":"Du","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12072-015-9633-1","article-title":"Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease","volume":"9","author":"Mostafa","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CEJ.0000000000000172","article-title":"Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis","volume":"25","author":"Shirakami","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","author":"Wang","year":"2017","journal-title":"Nat. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2020.04.034","article-title":"STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus","volume":"73","author":"Rinella","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Lefebvre, E., Moyle, G., Reshef, R., Richman, L.P., Thompson, M., Hong, F., Chou, H.L., Hashiguchi, T., Plato, C., and Poulin, D. (2016). Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.4049\/jimmunol.0900205","article-title":"Regulation of inflammatory monocyte\/macrophage recruitment from the bone marrow during murine cytomegalovirus infection: Role for type I interferons in localized induction of CCR2 ligands","volume":"183","author":"Crane","year":"2009","journal-title":"J. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dio xo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor beta agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.14218\/JCTH.2020.00027","article-title":"Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications","volume":"8","author":"Kizivat","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.cct.2021.106335","article-title":"The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"104","author":"Abdelmalek","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"ref_152","first-page":"7449","article-title":"A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients","volume":"25","author":"Fouda","year":"2021","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12664-020-01131-x","article-title":"Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis\u2014A randomized pilot study","volume":"40","author":"Kedarisetty","year":"2021","journal-title":"Indian J. Gastroenterol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MCO.0b013e3283547171","article-title":"Role of fibroblast growth factor 19 in the control of glucose homeostasis","volume":"15","author":"Schaap","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fphys.2019.00419","article-title":"FGF21 as Modulator of Metabolism in Health and Disease","volume":"10","author":"Tezze","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2147\/DMSO.S317096","article-title":"Advances in Biological Functions and Clinical Studies of FGF21","volume":"14","author":"Lin","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_158","unstructured":"Zhou, M., Kreft, I., Woo, S.-H., Chrungoo, N., and Wieslander, G. (2016). Chapter nine\u2014Genetic Resources of Buckwheat in India. Molecular Breeding and Nutritional Aspects of Buckwheat, Academic Press."},{"key":"ref_159","first-page":"1487","article-title":"New concepts in nutraceuticals as alternative for pharmaceuticals","volume":"5","author":"Nasri","year":"2014","journal-title":"Int. J. Prev. Med."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Salvoza, N., Giraudi, P.J., Tiribelli, C., and Rosso, N. (2022). Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052764"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Cicero, A.F., Colletti, A., and Bellentani, S. (2018). Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): The available clinical evidence. Nutrients, 10.","DOI":"10.3390\/nu10091153"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"105517","DOI":"10.1016\/j.phrs.2021.105517","article-title":"Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease","volume":"166","author":"Zhao","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbadis.2018.10.010","article-title":"Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice","volume":"1865","author":"Presa","year":"2019","journal-title":"Biochim Biophys Acta Mol. Basis Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/ijpvm.IJPVM_499_17","article-title":"Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials","volume":"10","author":"Hariri","year":"2019","journal-title":"Int. J. Prev. Med."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Barchetta, I., Cimini, F.A., and Cavallo, M.G. (2017). Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. Nutrients, 9.","DOI":"10.3390\/nu9091015"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"111092","DOI":"10.1016\/j.nut.2020.111092","article-title":"Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"83","author":"Kalopitas","year":"2021","journal-title":"Nutrition"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/gastroent12020014","article-title":"Expert opinion on the management of Non-alcoholic fatty liver disease (NAFLD) in the Middle east with a focus on the use of silymarin","volume":"12","author":"Hashem","year":"2021","journal-title":"Gastroenterol. Insights"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Savic, D., Hodson, L., Neubauer, S., and Pavlides, M. (2020). The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD). Nutrients, 12.","DOI":"10.3390\/nu12082178"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.1039\/D2FO02570A","article-title":"Dietary supplementation of L-carnitine ameliorates metabolic syndrome independent of trimethylamine N-oxide produced by gut microbes in high fat diet induced obese mice","volume":"13","author":"Gao","year":"2022","journal-title":"Food Funct."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Oh, H., Park, C.H., and Jun, D.W. (2022). Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071053"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"689042","DOI":"10.3389\/fmed.2021.689042","article-title":"Role of carnitine in non-alcoholic fatty liver disease and other related diseases: An update","volume":"8","author":"Li","year":"2021","journal-title":"Front. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"106001","DOI":"10.1016\/j.phrs.2021.106001","article-title":"The current use and evolving landscape of nutraceuticals","volume":"175","author":"Chopra","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Colletti, A., Fratter, A., Pellizzato, M., and Cravotto, G. (2022). Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. Nutrients, 14.","DOI":"10.3390\/nu14224769"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"103418","DOI":"10.1016\/j.jddst.2022.103418","article-title":"Nanotechnology: An approach to overcome bioavailability challenges of nutraceuticals","volume":"72","author":"Manocha","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/19390211.2021.1874587","article-title":"The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease","volume":"19","author":"Poulos","year":"2022","journal-title":"J. Diet. Suppl."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12967-022-03579-1","article-title":"A new nutraceutical (Livogen Plus\u00ae) improves liver steatosis in adults with non-alcoholic fatty liver disease","volume":"20","author":"Ferro","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-981-10-8684-7_9","article-title":"Microbiota, Obesity and NAFLD","volume":"1061","author":"Lau","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/4441009a","article-title":"Physiology: Obesity and gut flora","volume":"444","author":"Bajzer","year":"2006","journal-title":"Nature"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Llopis","year":"2013","journal-title":"Gut"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Vallianou, N., Christodoulatos, G.S., Karampela, I., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D., and Dalamaga, M. (2021). Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules, 12.","DOI":"10.3390\/biom12010056"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_183","first-page":"237","article-title":"Probiotics: Achieving a better regulatory fit","volume":"69","author":"Hoffmann","year":"2014","journal-title":"Food Drug Law J."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1038\/ijos.2017.51","article-title":"Analysis of differential expression of tight junction proteins in cultured oral epithelial cells altered by Porphyromonas gingivalis, Porphyromonas gingivalis lipopolysaccharide, and extracellular adenosine triphosphate","volume":"10","author":"Guo","year":"2018","journal-title":"Int. J. Oral Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1007\/s10620-019-05699-z","article-title":"Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis","volume":"64","author":"Liu","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Carpi, R.Z., Barbalho, S.M., Sloan, K.P., Laurindo, L.F., Gonzaga, H.F., Grippa, P.C., Zutin, T.L.M., Girio, R.J.S., Repetti, C.S.F., and Detregiachi, C.R.P. (2022). The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158805"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5946\/ce.2019.009","article-title":"Fecal Microbiota Transplantation: An Update on Clinical Practice","volume":"52","author":"Kim","year":"2019","journal-title":"Clin. Endosc."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/nmicrobiol.2016.15","article-title":"Faecal microbiota transplantation is promising but not a panacea","volume":"1","author":"Sadowsky","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals with Steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12967-021-02865-8","article-title":"Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response","volume":"19","author":"Tang","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1182\/blood-2021-153769","article-title":"Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Mitoxantrone, Etoposide, and Cytarabine (MEC)-Based Combination Therapy in Refractory & Relapsed Acute Myeloid Leukemia (AML) Patients","volume":"138","author":"Marcucci","year":"2021","journal-title":"Blood"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.2174\/1381612825666190117114305","article-title":"The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease","volume":"24","author":"Doumas","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_196","unstructured":"(2022, September 10). Risk Evaluation and Mitigation Strategies|REMS, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems."},{"key":"ref_197","unstructured":"Eggleton, J.S., and Jialal, I. (2022). Thiazolidinediones, StatPearls Publishing."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"E1756","DOI":"10.1210\/jc.2011-0615","article-title":"Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity","volume":"96","author":"McLaughlin","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11914-010-0027-y","article-title":"Bone loss in diabetes: Use of antidiabetic thiazolidinediones and secondary osteoporosis","volume":"8","year":"2010","journal-title":"Curr. Osteoporos Rep."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.cgh.2014.05.010","article-title":"Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease","volume":"12","author":"Vuppalanchi","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Di Mauro, S., Scamporrino, A., Filippello, A., Di Pino, A., Scicali, R., Malaguarnera, R., Purrello, F., and Piro, S. (2021). Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111905"},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Kamada, Y., Akita, M., Takeda, Y., Yamada, S., Fujii, H., Sawai, Y., Doi, Y., Asazawa, H., Nakayama, K., and Mizutani, K. (2013). Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066328"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: A population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.coph.2021.07.007","article-title":"An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities","volume":"60","author":"Pan","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"100148","DOI":"10.1016\/j.jhepr.2020.100148","article-title":"Stratification of patients in NASH clinical trials: A pitfall for trial success","volume":"2","author":"Ampuero","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jhep.2021.09.002","article-title":"NAFLD vs. MAFLD\u2013It is not the name but the disease that decides the outcome in fatty liver","volume":"76","author":"De","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"ref_212","first-page":"103418","article-title":"Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons","volume":"72","author":"Tacke","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Valenzuela-Vallejo, L., Guatibonza-Garc\u00eda, V., and Mantzoros, C.S. (2022). Recent Guidelines for Non-Alcoholic Fatty Liver Disease (NAFLD): Are They Already Outdated and in Need of Supplementation?, Elsevier.","DOI":"10.1016\/j.metabol.2022.155248"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00125-019-05024-3","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: Assessing the evidence for causality","volume":"63","author":"Brouwers","year":"2020","journal-title":"Diabetologia"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fphar.2018.01566","article-title":"Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: Insulin resistance between hepatic and peripheral tissues","volume":"9","author":"Mu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr. Diabetes Rep."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3350\/cmh.2022.0019","article-title":"Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial","volume":"28","author":"Oh","year":"2022","journal-title":"Clin. Mol. Hepatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:47:16Z","timestamp":1760147236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":217,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24010158"],"URL":"https:\/\/doi.org\/10.3390\/ijms24010158","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]}}}